Experts agreed that the biggest threat to progress on overdose deaths is the looming Medicaid cuts. Researchers at Penn’s ...
Analysts say private deals involve drugmakers agreeing to lower prices in Medicaid, where prices are low, in return for no ...
A startup tackling the 'dumb problems' at the intersection of AI and bio, accuracy of AI scribes, and more.
UniQure has submitted its Huntington’s gene therapy to the FDA, investors remain unenthusiastic on Novo Nordisk, and more of ...
The next DSM and the algorithm, an unexpected discovery on alpha-gal syndrome, and more health news from Morning Rounds ...
The new DSM, expected in 2030, should address the digital environments of eating disorders patients, experts write.
Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.
The whole of my field has been flattened into a single lazy question: Did the health care system fail her?” writes Jennifer ...
The federal spending bill has an important provision for researchers, and Trump announced more MFN deals with pharma firms.
UniQure submitted applications to the FDA and the UK’s MHRA, seeking the marketing approval of AMT-130, its treatment for ...
Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for ...
Shihipar directs narrative projects and policy impact initiatives at the People, Place, and Health Collective at the Brown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results